ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2259

Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey

V. Strand1, C. Galateanu2, S. Lobosco3, D.S. Pushparajah2, J. Sayers4 and R.F. van Vollenhoven5, 1Stanford University, Portola Valley, CA, 2UCB Pharma, Brussels, Belgium, 3Adelphi Real World Ltd., Macclesfield, United Kingdom, 4Adelph Real World Ltd., Macclesfield, United Kingdom, 5Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Patient Satisfaction, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Current SLE treatment regimens follow an ‘add-on’ paradigm: typically, therapies are added as the activity of a patient’s disease increases. Most current treatments, particularly corticosteroids (CS) and immunosuppressants (IM), frequently have severe side effects that contribute to damage in SLE. This abstract reports an analysis of data drawn from a cross-sectional survey of physicians and their consulting lupus patients.

Methods:

Data were extracted from the Adelphi Real World Lupus Disease-Specific Programme (DSP), a cross-sectional survey of 233 physicians and their patients conducted between December 2009 and May 2010 in the USA, France, Germany, Italy, Spain, and the UK. Each physician completed a comprehensive patient record form for their five most recently seen SLE patients. Data collected included subjective rating of disease activity, flare occurrence, treatment satisfaction, and drug classes received. Patients were invited to fill out a self-completion questionnaire, which included EQ5D and the FACIT fatigue scale. This analysis focused on three key drug classes: CS, IM, and antimalarials (AM).

Results:

The Adelphi Lupus DSP survey included 886 patients, of whom 515 completed a self-assessment questionnaire. The population was 90% female with a mean age of 42 years. A total of 618 patients (70%) were classified as having mild disease activity, compared to 247 (28%) with moderate disease activity, and 21 (2%) with severe disease activity. The numbers of patients in each disease activity group flaring in the last 12 months were 138 (22.3%), 126 (51.0%), and 12 (57.1%), respectively. The proportions of patients receiving different regimens are listed in the table. SLE treatment regimens including CS (with or without other classes) were associated with more active disease (p < 0.0001) as were regimens that included ≥ 2 drug classes (p < 0.001). Patients reporting flares were more likely to be receiving ≥ 2 vs < 2 key drug classes (p < 0.001). A greater proportion of patients reported satisfaction with their treatment regimen when it did not include CS than when it did (81% vs 68%; p < 0.01). Patients receiving CS reported lower mean EQ5D than those who were not (0.731 vs 0.792; p = 0.0002). However, those receiving CS did report better fatigue levels than those who were not (35.0 vs 38.4, p = 0.0001). A greater proportion of physicians also reported more satisfaction with their patient's treatment regimen when it did not include CS (p < 0.001).

Conclusion:

More active disease is associated with flare in the last 12 months, ≥ 2 classes of therapy, and use of CS specifically. Unexpectedly, physicians and patients accepted moderate or high levels of disease activity while receiving multiple medications, suggesting that they had become resigned to uncontrolled disease activity. These results support the need for new therapies for SLE, and treatment algorithms incorporating such therapies.


Disclosure:

V. Strand,

UCB Pharma,

5;

C. Galateanu,

UCB Pharma,

3;

S. Lobosco,

Adelphi Real World Ltd.,

3,

UCB Pharma,

5;

D. S. Pushparajah,

UCB Pharma,

3;

J. Sayers,

Adelphi Real World Ltd.,

3,

UCB Pharma,

5;

R. F. van Vollenhoven,

Abbott Laboratories,

5,

Bristol Myers-Squibb,

5,

GlaxoSmithKline,

5,

Human Genome Sciences, Inc.,

5,

MSD,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

UCB Pharma,

5,

Abbott Laboratories,

2,

Bristol Myers-Squibb,

2,

GlaxoSmithKline,

2,

Human Genome Sciences, Inc.,

2,

MSD,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

UCB Pharma,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/limitations-of-current-treatment-for-systemic-lupus-erythematosus-a-patient-and-physician-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology